Photo by sxy_selia from unsplash
Medicinal products based on genome editing must undergo rigorous preclinical testing and are subject to regulatory oversight for proper risk assessment prior to first evaluation in humans. We give a… Click to show full abstract
Medicinal products based on genome editing must undergo rigorous preclinical testing and are subject to regulatory oversight for proper risk assessment prior to first evaluation in humans. We give a European perspective on the regulatory expectations to translate genome editing to the clinic to ensure their timely progress to market.
Keywords:
genome editing;
race loosening;
human genome;
editing race;
regulatory standards;
loosening regulatory
Journal Title: Trends in biotechnology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Trends in biotechnology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!